Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial-Reference-Cited by-同舟云学术

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

Published:2018-07 Issue:1 Volume:155 Page:29-32
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Beatty Gregory L.,O’Hara Mark H.,Lacey Simon F.,Torigian Drew A.,Nazimuddin Farzana,Chen Fang,Kulikovskaya Irina M.,Soulen Michael C.,McGarvey Maureen,Nelson Anne Marie,Gladney Whitney L.,Levine Bruce L.,Melenhorst J. Joseph,Plesa Gabriela,June Carl H.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference14 articles.

1. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

2. Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

3. Signatures of mutational processes in human cancer

4. Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer

Cited by 362 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. mRNA-based therapeutic strategies for cancer treatment;Molecular Therapy;2024-09

2. Advances and prospects of RNA delivery nanoplatforms for cancer therapy;Acta Pharmaceutica Sinica B;2024-09

3. mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends;Biomarker Research;2024-08-31

4. Scarless circular mRNA-based CAR-T cell therapy elicits superior anti-tumor efficacy;2024-08-05

5. Finding Your CAR;The American Journal of Pathology;2024-08